- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02363075
Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia (DXA)
A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Quality of life of patients with stabilized gliomas is often impacted by a severe physical and psychological fatigue resulting from both tumor and side effects of treatments.
It is a randomized double blind Placebo-Controlled Trial evaluating the effect of dexamfetamine sulphate on severe fatigue in glioma patients. Half of the participants will receive dexamfetamine sulphate and the other half will receive a placebo. Neither the participant nor the study doctor will know what group they are in.
The main objective is to assess the impact at 3 months of dexamfetamine sulphate in patients suffering from a RANO stable or responsive glioma complaining of a severe fatigue (quantified by the Multidimensional Fatigue inventory - MFI 20 scale).
The secondary objectives include: evaluation of side effects, quality of life, cognitive functions, depression, variation in time of both fatigue scales MFI 20 and VAS.
58 patients will be included. In patients complaining of severe asthenia, with a non progressive neuro-oncological disease, and without criteria of depression revealed by HAD (Hospital Anxiety and Depression) scale, evaluation of fatigue will be done with the MFI 20 scale. Patients with a MFI 20 score ≥60/100 and corresponding to inclusion criteria will be invited to participate.
After randomisation, a baseline evaluation will be done, including MFI20, Norris VAS, EORTC QLQ-C30, Mattis scale, Trail Making Test, Grober and Buschke, Wisconsin Card Sorting Test , HAD scale and Marin scale.
Patients will receive, in a double blinded way, six pills a day either of dexamphetamine sulfate (15 mg*2) or of placebo, during 3 months, after an initial phase of progressive increasing levels of dose every 10 days, depending on tolerance.
The evaluation of fatigue, quality of life will be done every month during the 3 months of treatment. The cognitive evaluation will be done at 3 months.
The main criteria of evaluation is the variation during 3 months of the MFI 20 score in non progressive patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Florence LAIGLE-DONADEY, MD
- Email: florence.laigle-donadey@psl.aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Groupe Hospitalier Pitie Salpetriere
-
Contact:
- Florence Laigle-Donadey, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Patients complaining of a severe asthenia defined as a MFI 20 score ≥ 60/100
- Patients suffering from histologically proven gliomas
- Patients with responsive or stable disease (according to RANO criteria) for at least 3 months, either still on chemotherapy or only being under simple surveillance
- stable dosage of steroids for at least 1 week
- Time elapsed post-radiotherapy more than 3 months
- HAD score of depression ≤8
- Karnofsky performance index ≥ 60
- ≥ 18 years of age
- contraceptive measures
- written informed consent
- Depending from the french system of health assurance
Exclusion criteria :
- Severe aphasia or other symptoms compromising the tests execution
- concomitant uncontrolled pathology
- Known symptomatic or constitutional cardiovascular disease, (cardiac arrhythmia, recent myocardial infarction, chest pain, history of unstable angina) and/or uncontrolled hypertension, (≥ 16/10), arteriosclerosis, cardiac abnormality detected at the initial cardiac echography.
- Hyperthyroidism
- Known hypersensitivity to dexamphetamine or related compounds
- Glaucoma
- Porphyria
- Hemoglobin level of less than 10,0 g/dL
- Alcohol or drug abuse,
- Agitation
- Tourette's syndrome
- Patients who have been receiving MAO inhibitors during the past 14 days
- Hereditary hypersensitivity to galactose, Lapp lactase deficiency or glucose-galactose malabsorption syndrome
- Hereditary hypersensitivity to saccharose, glucose-galactose malabsorption syndrome or saccharase-isomaltase deficiency
- Pregnant or lactating woman
- Non french speaker
- History of psychiatric disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dexamfetamine sulphate
Dexamfetamine Sulphate 5 mg Tablets
|
10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
|
Placebo Comparator: placebo
Aspect tablets identical to the active
|
10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Multidimensional Fatigue inventory - MFI 20 scale score
Time Frame: 3 months
|
improvement of the MFI 20 score between the inclusion and the evaluation at 3 months in case of non progressive disease during this period of time.
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Florence LAIGLE-DONADEY, MD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Asthenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Dextroamphetamine
Other Study ID Numbers
- P110501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on Dexamfetamine sulphate
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingAttention Deficit Disorder With HyperactivityNetherlands
-
Eurofarma Laboratorios S.A.CompletedOsteoarthritis of the KneeBrazil
-
Ullevaal University HospitalUnknownPrimary and Secondary Osteoarthritis in HipNorway
-
University of SydneyNational Health and Medical Research Council, AustraliaUnknown
-
University of LausannePierre Fabre LaboratoriesCompletedFatigue | Iron DeficiencySwitzerland
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Cutaneous Neurofibroma | Optic Nerve GliomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | KRAS NP_004976.2:p.G12RUnited States
-
SlidgigtinstituttetPharma NordCompleted
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditionsUnited States, Puerto Rico